Works matching DE "THERAPEUTIC use of antineoplastic agents"
Results: 5000
THE PROTECTIVE ROLE OF INTESTINAL MICROBIOTA IN COLORECTAL CANCER TREATMENT: A SCOPING REVIEW.
- Published in:
- Texto & Contexto Enfermagem, 2024, v. 33, p. 1, doi. 10.1590/1980-265X-TCE-2024-0109en
- By:
- Publication type:
- Article
QUIMIO EM CASA: APPLICATION FOR FAMILY MEMBERS OF CHILDREN AND ADOLESCENTS USING ORAL ANTINEOPLASTIC AGENTS.
- Published in:
- Texto & Contexto Enfermagem, 2022, v. 31, p. 1, doi. 10.1590/1980-265X-TCE-2021-0414en
- By:
- Publication type:
- Article
Neoadjuvant pembro shows benefit in MIBC.
- Published in:
- Urology Times, 2021, v. 49, n. 10, p. 7
- By:
- Publication type:
- Article
Olaparib/pembrolizumab, focal therapy, and ultrasonic propulsion of stones: AUA 2021 highlights.
- Published in:
- 2021
- By:
- Publication type:
- Proceeding
UroPipeline.
- Published in:
- Urology Times, 2021, v. 49, n. 10, p. 5
- By:
- Publication type:
- Article
Emerging Treatment Options for the Management of Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Urology Times, 2021, v. 49, n. 9, p. 33
- By:
- Publication type:
- Article
What have been the biggest changes in the way you treat prostate cancer?
- Published in:
- 2021
- Publication type:
- Interview
EV-301 investigator discusses enfortumab vedotin: "Significant survival advantage" vs chemotherapy was observed.
- Published in:
- 2021
- By:
- Publication type:
- Interview
Analysis backs genomic testing for optimal apalutamide use in nmCRPC: Microarray-based assay identified potential biomarkers of response to treatment.
- Published in:
- Urology Times, 2021, v. 49, n. 8, p. 16
- By:
- Publication type:
- Article
Pembrolizumab/axitinib RCC survival bene?t is sustained in long-term results: Median OS was 45.7 months with the combination vs 40.1 months with sunitinib.
- Published in:
- Urology Times, 2021, v. 49, n. 7, p. 17
- By:
- Publication type:
- Article
NCCN adds lenvatinib/pembrolizumab to Category 1 recommendation.
- Published in:
- Urology Times, 2021, v. 49, n. 5, p. 34
- By:
- Publication type:
- Article
CTC mutations may predict hormone therapy outcomes in mCRPC.
- Published in:
- Urology Times, 2021, v. 49, n. 5, p. 22
- By:
- Publication type:
- Article
Rucaparib plus enzalutamide shows early promise in metastatic CRPC.
- Published in:
- Urology Times, 2021, v. 49, n. 5, p. 22
- By:
- Publication type:
- Article
PHASE 3 TRIAL TO EXPLORE RCC COMBINATION.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 34
- By:
- Publication type:
- Article
Combination of belzutifan plus cabozantinib is active in advanced RCC: Treatment shrank tumors in 88% of patients and led to a disease control rate of 90%.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 34
- By:
- Publication type:
- Article
Bipolar androgen therapy sensitizes CRPC to subsequent treatment: Patient-reported QOL data consistently favored BAT over enzalutamide, investigators report.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 11
- By:
- Publication type:
- Article
UroPipeline.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 7
- By:
- Publication type:
- Article
Noncastrate advanced prostate cancer guideline receives update: Panel outlines 4 standards of care for the initial treatment of noncastrate metastatic disease.
- Published in:
- Urology Times, 2021, v. 49, n. 3, p. 11
- By:
- Publication type:
- Article
Onvansertib is active in patients with abiraterone-resistant prostate cancer: More than one-third of patients undergoing treatment had disease control at 12 weeks.
- Published in:
- Urology Times, 2021, v. 49, n. 3, p. 10
- By:
- Publication type:
- Article
Apalutamide plus abiraterone reduces risk of progression in metastatic CRPC: Radiographic progression-free survival benefit was sustained across prespecified subgroups.
- Published in:
- Urology Times, 2021, v. 49, n. 3, p. 9
- By:
- Publication type:
- Article
Olaparib antitumor activity sustained across HRR gene subtypes in metastatic CRPC: Greatest benefit occurred in patients with BRCA1/BRCA2 mutations, data indicate.
- Published in:
- Urology Times, 2021, v. 49, n. 3, p. 8
- By:
- Publication type:
- Article
Enzalutamide plus ADT improves PFS in men with bone and/or lymph node metastases.
- Published in:
- Urology Times, 2021, v. 49, n. 2, p. 11
- By:
- Publication type:
- Article
FDA approves label update for darolutamide in nonmetastatic CRPC.
- Published in:
- Urology Times, 2021, v. 49, n. 2, p. 7
- By:
- Publication type:
- Article
PARP inhibitors: What urologists need to know.
- Published in:
- 2021
- By:
- Publication type:
- Interview
Subgroup data sustain enzalutamide PFS benefit in nonmetastatic CRPC.
- Published in:
- Urology Times, 2021, v. 49, n. 1, p. 18
- By:
- Publication type:
- Article
How to get started with immunotherapy.
- Published in:
- Urology Times, 2021, v. 49, n. 1, p. 1
- By:
- Publication type:
- Article
Expert provides update on treatments for BCG-unresponsive NMIBC: Pembrolizumab and nadofaragene firadenovec show promise in non--muscle-invasive bladder cancer.
- Published in:
- Urology Times, 2020, v. 48, n. 12, p. 28
- By:
- Publication type:
- Article
Expert: 2020 marks dawn of the precision medicine era in prostate cancer: FDA approval of PARP inhibitors olaparib and rucaparib has launched new era, investigator says.
- Published in:
- Urology Times, 2020, v. 48, n. 12, p. 19
- By:
- Publication type:
- Article
UroPipeline.
- Published in:
- Urology Times, 2020, v. 48, n. 12, p. 8
- By:
- Publication type:
- Article
Why is rucaparib response higher in BRCA2-mutated prostate cancer? Investigators present 2 hypotheses for variance in sensitivity to PARP inhibition.
- Published in:
- Urology Times, 2020, v. 48, n. 11, p. 23
- By:
- Publication type:
- Article
Cabozantinib combo induces clinical activity in advanced ccRCC.
- Published in:
- Urology Times, 2020, v. 48, n. 10, p. 41
- By:
- Publication type:
- Article
Nephrectomy after immunotherapy can achieve CR in selected patients.
- Published in:
- Urology Times, 2020, v. 48, n. 10, p. 40
- By:
- Publication type:
- Article
FDA approval is sought for nivolumab/ cabozantinib combo in kidney cancer.
- Published in:
- Urology Times, 2020, v. 48, n. 10, p. 6
- By:
- Publication type:
- Article
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 1, p. 1, doi. 10.1007/s40267-024-01045-0
- By:
- Publication type:
- Article
Preferably pre-empt pathological scars, or pick from a plethora of therapies.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 1, p. 22, doi. 10.1007/s40267-023-01040-x
- By:
- Publication type:
- Article
The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 432, doi. 10.1007/s40267-023-01038-5
- By:
- Publication type:
- Article
The role of belzutifan, an inhibitor of hypoxia-inducible factor, for renal cell carcinoma in adults with Von Hippel–Lindau disease: a review.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 11, p. 388, doi. 10.1007/s40267-023-01031-y
- By:
- Publication type:
- Article
Tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer: a profile of its use in the USA.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 9, p. 382, doi. 10.1007/s40267-022-00939-1
- By:
- Publication type:
- Article
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 6, p. 261, doi. 10.1007/s40267-022-00922-w
- By:
- Publication type:
- Article
Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 5, p. 222, doi. 10.1007/s40267-022-00915-9
- By:
- Publication type:
- Article
Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer.
- Published in:
- Journal of Women's Health (15409996), 2024, v. 33, n. 11, p. 1509, doi. 10.1089/jwh.2023.0971
- By:
- Publication type:
- Article
Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation.
- Published in:
- Strahlentherapie und Onkologie, 2022, v. 198, n. 1, p. 66, doi. 10.1007/s00066-021-01840-y
- By:
- Publication type:
- Article
Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Risikostratifizierung der Lungentoxizität einer Kombination von Bestrahlung der gesamten Lunge und Hochdosischemotherapie bei Patienten mit Ewing-Sarkom und Lungenmetastasen – eine Übersicht.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Diffusion-weighted imaging as a follow-up modality for evaluation of major salivary gland function in nasopharyngeal carcinoma patients: a preliminary study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Einfluss der präoperativen Therapie auf die prognostische Gensignatur CINSARC: Translationale Forschungsergebnisse einer Phase-1-Studie der deutschen interdisziplinären Sarkomstudiengruppe (GISG 03).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Ergebnisse der lokoregionalen Strahlentherapie bei metastatischen kastrationsresistenten und mit Abirateronacetat behandelten Prostakarzinompatienten.
- Published in:
- 2019
- By:
- Publication type:
- journal article